4. Danaher Corporation (NYSE:DHR)
Danaher Corporation (NYSE: DHR) reaches No. 4 after undergoing a major corporate transformation that has made the company increasingly focused on life sciences, biotechnology and diagnostics.
The transformation did not happen overnight.
Between 2019 and 2023, Danaher Corporation (NYSE: DHR) acquired and divested several important businesses, gradually reshaping a diversified industrial organization into a company much more heavily exposed to healthcare and life sciences.
CFRA analyst Sel Hardy believes the result is a stronger and more focused investment.
Among the company’s important businesses are Cytiva, which provides technologies used in bioprocessing and biologic drug manufacturing; Beckman Coulter, known for diagnostic and laboratory systems; and molecular diagnostic technologies associated with GeneXpert.
That puts Danaher Corporation (NYSE: DHR) in an attractive position because modern medicine increasingly depends on sophisticated diagnostics and biologic manufacturing.
Perhaps more surprisingly, Danaher Corporation (NYSE: DHR) also offers indirect exposure to the GLP-1 boom.
When investors think about obesity drugs, attention naturally goes to the pharmaceutical companies selling them. Yet producing and analyzing complex medicines requires an enormous ecosystem of laboratory tools, chromatography equipment and bioprocessing systems.
Danaher Corporation (NYSE: DHR) participates in that ecosystem through liquid chromatography-mass spectrometry instrumentation and biologics processing businesses.
That makes Danaher Corporation (NYSE: DHR) something of a picks-and-shovels healthcare investment.
During historical gold rushes, investors sometimes discovered that selling equipment to miners could be more predictable than searching for gold directly. A similar logic can apply in biotechnology. Instead of betting exclusively on which individual drug becomes a blockbuster, investors can own companies providing tools used across many pharmaceutical research and manufacturing programs.
Danaher Corporation (NYSE: DHR) fits that description particularly well.
CFRA gives Danaher Corporation (NYSE: DHR) a “buy” rating and a $225 price target, compared with a July 30 closing price of $196.17. That implies roughly 15% potential upside based on the supplied figures.
Longer term, the case rests on something bigger than a price target. Global pharmaceutical research is becoming increasingly sophisticated, biologic medicines continue expanding and diagnostic technology remains central to modern healthcare.
Because Danaher Corporation (NYSE: DHR) supplies the infrastructure supporting those trends, it can potentially benefit without needing to predict which individual medicine will become the next pharmaceutical blockbuster.
For investors looking for life sciences stocks, diagnostics stocks, GLP-1-related investments and diversified healthcare stocks to buy in 2026, Danaher Corporation (NYSE: DHR) offers a particularly interesting combination.
